Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EBP | Q15125 | 2/20 | 0.70 |
| ▸ | DHCR7 | Q9UBM7 | 2/20 | 0.70 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31212431 | 1.00 | EBP (0.70) | EBPDHCR7EPHX2TSHRLMNA | |
| SCHEMBL17007470 | 0.93 | EBP (0.66) | EBPDHCR7EPHX2TSHRLMNA | |
| SCHEMBL22033227 | 0.82 | EBP (1.00) | EBPDHCR7EPHX2 | |
| SCHEMBL17019488 | 0.82 | EBP (0.53) | EBPDHCR7EPHX2TSHRLMNA | |
| SCHEMBL20993844 | 0.81 | EBP (0.63) | EBPDHCR7EPHX2LMNA | |
| SCHEMBL22032768 | 0.81 | EBP (0.62) | EBPDHCR7EPHX2ALDH1A1SMN1; SMN2 | |
| SCHEMBL3813872 | 0.81 | MEN1 (0.75) | TSHRLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL13743135 | 0.80 | MEN1 (0.58) | TSHRLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL7925677 | 0.79 | EBP (0.61) | EBPDHCR7EPHX2ALDH1A1MEN1 | |
| SCHEMBL22032774 | 0.79 | ALDH1A1 (0.62) | EBPDHCR7EPHX2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12139461-B1 | Piperidine compounds as PDE5 inhibitors | KING SAUD UNIVERSITY (SA) | 2024-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139461-B1 | Piperidine compounds as PDE5 inhibitors | PDE5A, PDE3A, PDE2A | EBP 3339/4885DHCR7 1628/4885EPHX2 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.